FDA Approves First Fixed-Dose OTC of Acetaminophen and Naproxen

The FDA approved Tylenol with naproxen, the first and only OTC fixed-dose combination of acetaminophen and naproxen sodium, Kenvue announced. The product combines 650 mg of acetaminophen with 220 mg of naproxen sodium, a nonsteroidal anti-inflammatory drug (NSAID), in a single dose that begins working in under 30 minutes and provides relief for 12 hours.¹

The approval comes as Kenvue points to a persistent gap in pain relief satisfaction. According to the company's Kenvue Pain Consumer Survey (March 2026; n = 6240), an estimated 75% of persistent pain sufferers report dissatisfaction with their current relief options. Kenvue also cited US Department of Labor data indicating up to 1 in 4 patients prescribed opioids are at risk of addiction, positioning the new combination as a nonopioid alternative for patients who might otherwise navigate multiple single-ingredient products or prescription options on their own.¹

Clinical Evidence Behind the Approval

Kenvue said the approval was supported by 8 clinical studies demonstrating that the fixed-dose combination produced superior pain relief compared with acetaminophen alone and with naproxen sodium alone (Aleve, 220 mg). Data from those studies are expected to be presented at upcoming medical congresses, including PAINWeek 2026.¹

"This milestone reflects the long-standing leadership of Tylenol in translating rigorous clinical science into accessible, over-the-counter solutions," Rajesh Mishra, MD, PhD, chief medical officer of Kenvue, said in the news release.¹

The FDA has granted Kenvue a 3-year period of exclusivity for the new OTC formulation. The product is described as coming soon to major US retailers nationwide, building on more than 70 years of the Tylenol brand's history in OTC analgesic development, including the first children's liquid acetaminophen product and the introduction of 500 mg Extra Strength Tylenol.¹

What Pharmacists Should Know About the Individual Ingredients

Because Tylenol® with Naproxen combines 2 analgesics with distinct safety profiles, pharmacists fielding questions about the product may want to revisit the counseling points associated with each ingredient individually.

Acetaminophen is used to treat mild to moderate pain and reduce fever. Patients should be asked about frequent alcohol use, liver disease, allergic reactions to acetaminophen, and pregnancy or breastfeeding status before use and should be cautioned against taking other acetaminophen-containing products concurrently.²

Acetaminophen interacts with alcohol, imatinib, and isoniazid, and taking too much can cause liver damage. Patients who suspect an overdose should seek medical help immediately even without symptoms. Liver injury warning signs include right upper abdominal pain, loss of appetite, nausea, light-colored stool, dark urine, and yellowing of the skin or eyes.²

Naproxen, an NSAID, carries its own set of precautions that pharmacists routinely counsel on for arthritis, gout, and other pain indications. The medication may raise the risk of heart attack or stroke, particularly in patients with existing heart disease or those using it long-term, and can cause stomach or intestinal bleeding without warning signs.³

Patients with a history of stomach ulcers, those who smoke or drink alcohol regularly, people over 60, and those in poor health face elevated risk. Naproxen should not be used to manage pain immediately before or after heart surgery such as coronary artery bypass grafting, and it is contraindicated in patients with aspirin-sensitive asthma or severe kidney disease.³

It also carries a long list of drug interactions, including with anticoagulants, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and other NSAIDs and salicylates.³

A Familiar Counseling Dilemma, Now in One Product

The tension between acetaminophen and NSAID therapy is one community pharmacists already navigate regularly. In a 2024 survey of 71 community pharmacists in Norway published in the journal Pharmacy, more than 80% of respondents said they preferred paracetamol (acetaminophen) over ibuprofen, citing acetaminophen's perceived lower risk profile, particularly in pregnancy or gastrointestinal conditions, and its minimal interactions with other drugs and food.⁴

That same survey found pharmacists rated their knowledge of laws and regulations around analgesics as medium to high, and nearly 80% wanted additional pain management training.⁴

A fixed-dose product that combines both drug classes may shift that counseling conversation. Rather than choosing between an NSAID and acetaminophen, patients now have a single OTC option that contains both, at doses (650 mg acetaminophen; 220 mg naproxen sodium) that carry the established risks of each ingredient rather than a novel safety profile.

Pharmacists will likely need to reinforce that patients should not add a separate acetaminophen or NSAID product on top of Tylenol with naproxen and should continue screening for the same contraindications—liver disease, cardiovascular risk, gastrointestinal bleeding history, kidney disease, and pregnancy—that apply to each ingredient individually.^2,3

Tylenol with naproxen is available without a prescription and is indicated for the temporary relief of pain. Kenvue's release directs consumers with questions about whether the product is appropriate for them to talk with a health care professional.¹

"The clinical program behind Tylenol with Naproxen was designed to answer a practical question: Could we deliver fast-onset and sustained pain relief in a single, opioid-free OTC option without asking patients to combine multiple products on their own?” Todd Bertoch, MD, chief medical officer of pain research at CenExel Clinical Research Inc, said in the news release.¹

REFERENCES

1. Kenvue. FDA approves Tylenol with Naproxen, the first and only over-the-counter fixed-dose combination of acetaminophen (650 mg) and naproxen sodium (220 mg). News release. Kenvue. July 24, 2026. Accessed July 27, 2026. https://www.kenvue.com/media/fda-approves-tylenol-with-naproxen

2. Acetaminophen (Tylenol). Cleveland Clinic. Accessed July 27, 2026. https://my.clevelandclinic.org/health/drugs/18829-acetaminophen-capsules-or-tablets

3. Naproxen (oral route). Mayo Clinic. Accessed July 27, 2026. https://www.mayoclinic.org/drugs-supplements/naproxen-oral-route/description/drg-20069820

4. Mujtaba SH, Gazerani P. Exploring the role of community pharmacists in pain management: enablers and challenges. Pharmacy. 2024;12(4):111. doi:10.3390/pharmacy12040111